Osteosarcopenia represents the convergence of osteoporosis and sarcopenia, with researchers identifying disrupted tryptophan metabolism as a key mechanistic driver alongside chronic inflammation and lipotoxicity. This dual pathology significantly amplifies risks beyond either condition alone, creating a cascade of functional decline, falls, and fragility fractures in aging adults. The tryptophan metabolism connection represents a potentially transformative insight, as this amino acid pathway regulates both muscle protein synthesis and bone formation through serotonin and kynurenine pathways. Current management remains fragmented—osteoporosis drugs for bone, resistance training and protein for muscle—but emerging strategies target shared mechanisms through hormonal modulators and metabolic interventions. The syndrome's clinical significance extends beyond simple additive effects; the bone-muscle crosstalk creates a self-reinforcing cycle of deterioration. While diagnostic criteria combining DEXA scans with sarcopenia assessments provide clearer identification, this review highlights a critical gap: most interventions still treat components separately rather than addressing the underlying metabolic convergence. The tryptophan metabolism finding could unlock unified therapeutic approaches, potentially transforming how we prevent and treat age-related musculoskeletal decline.